Brainstorm cell therapeutics announces full year 2023 financial results and provides corporate update

Conference call planned for early april 2024 to provide update on nurown program new york , april 1, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended december 31, 2023 and provided a corporate update. "brainstorm's priority for 2024 is to move forward with a confirmatory phase 3b trial for nurown that will potentially support a new biologics license application," said chaim lebovits, president and chief executive officer of brainstorm.
BCLI Ratings Summary
BCLI Quant Ranking